The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
Open accessAbstract
HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections. Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon. In this communication, we report the preclinical profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clinical development. The compound demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors. In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies. In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing. When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body weight twice daily (b.i.d.) for 7 days. Based on its preclinical profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clinically important resistance variants and highly suited for incorporation into newer all-oral regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,368
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon
Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M., & Wakita, T. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.023 · Cited by 590
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Farci, P. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00051-x · Cited by 467
Cited by
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Roth, D., Nelson, D. R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H., Martin, P., Pol, S., Londoño, M.-C., Hassanein, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00349-9 · Cited by 671
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Giordanetto, F., & Kihlberg, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 563
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Pawlotsky, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.003 · Cited by 518
Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ari, Z. B., Zhao, Y., Brown, D. D., Wan, S., DiNubile, M. J., Nguyen, B.-Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0785 · Cited by 516
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Bartenschlager, R., Lohmann, V., & Penin, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3046 · Cited by 402
Dore, G. J., Altice, F., Litwin, A. H., Dalgard, O., Gane, E. J., Shibolet, O., Luetkemeyer, A., Nahass, R., Peng, C.-Y., Conway, B., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0816 · Cited by 359
How Big Is Too Big for Cell Permeability?
Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00237 · Cited by 303
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Cell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
Hepatitis C virus NS3/4a protease inhibitors
McCauley, J. A., & Rudd, M. T. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.015 · Cited by 120
Self-citationProtease inhibitor therapy for hepatitis C virus-infection
de Leuw, P., & Stephan, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1454428 · Cited by 51
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Metadata
- Authors
- Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Di Filippo, M., Gates, A. T., Graham, D. J., Harper, S., Hazuda, D. J., McHale, C., Monteagudo, E., Pucci, V., Rowley, M., Rudd, M. T., Soriano, A., Stahlhut, M. W., Vacca, J. P., Olsen, D. B., Liverton, N. J., & Carroll, S. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-08
- Volume
- 56
- Issue
- 8
- Pages
- 4161-4167
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2130921346
- Cited by
- 259
- References
- 31
- FWCI
- 16.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.